Further evidence for the predictive validity of the unstable elevated exposed plus-maze, a behavioural model of extreme anxiety in rats: Differential effects of fluoxetine and chlordiazepoxide

Behavioural Pharmacology

Volumn 13, Issue 7, 2002, Pages 525-535

  Jones, Nick ^a   King, S M ^a   Duxon, M S ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Anxiety; Chlordiazepoxide; Escape; Flight; Fluoxetine; Handling; Panic; Plus maze; Rat

Indexed keywords

CHLORDIAZEPOXIDE; FLUOXETINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ESCAPE BEHAVIOR; EVIDENCE BASED MEDICINE; FLIGHT; FOOD; HUMAN; MALE; MAZE TEST; NONHUMAN; PANIC; RAT; VALIDATION PROCESS;

EID: 0036855832     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008877-200211000-00002     Document Type: Article

References (65)

1. Andrews N, File SE (1991). Handling of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. Eur J Pharmacol 235:109-112.
2. Argyropoulos SV, Nutt DJ (1999). The use of benzodiazepines in anxiety and other disorders. Eur Neuropsychopharmacol 9:S407-S412.
3. 1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 4:399-408.
4. Bakker A, van Balkom AJLM, van Dyck R (2000). Selective serotonin reuptake inhibitors in the treatment of panic disorder and agoraphobia. Int Clin Psychopharmacol 15:S25-S30.
5. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, et al. (1998). Consensus statement on panic disorder from the international consensus group on depression and anxiety. J Clin Psychiatry 59(suppl. 8):47-54.
6. Blanchard DC (1997). Stimulus and environmental control of defensive behaviours. In: The Functional Behaviorism of Robert C. Bolles: Learning, Motivation and Cognition. Bouton M, Faneslow M (editors). Washington DC: American Psychological Association, pp. 283-305.
7. Blanchard DC, Hori K, Rodgers RJ, Hendrie CA, Blanchard RJ (1989). Attenuation of defensive threat and attack in wild rats (Rattus rattus) by benzodiazepines. Psychopharmacology 97:392-401.
8. Blanchard DC, Popova NK, Plyusnina IZ, Velichko IL, Campbell D, Blanchard RJ, et al. (1994). Defensive reactions of 'wild type' and 'domesticated' wild rats to approach and contact by a threat stimulus. Aggress Behav 20:387-397.
9. Blanchard DC, Griebel G, Blanchard RJ (2001). Mouse defensive behaviours: Pharmacological and behavioural assays for anxiety and panic. Neurosci Biobehav Rev 25:205-218.
10. Blanchard RJ, Flannelly KJ, Blanchard DC (1986). Defensive behaviours of laboratory and wild Rattus norvegicus. J Comp Psychol 100:101-107.
11. Blanchard RJ, Griebel G, Henrie JA, Blanchard DC (1997). Differentiation of anxiolytic and panicolytic drugs by effects on rat and mouse defense test batteries. Neurosci Biobehav Rev 21:783-789.
12. Blanchard RJ, Hebert MA, Ferrari P, Palanza P, Figueira R, Blanchard DC, Parmigani S (1998). Defensive behaviours in wild and laboratory (Swiss) mice: The mouse defense test battery. Physiol Behav 65:201-209.
13. Catalano G, Hakala SM, Catalano MC (2000). Sertraline-induced panic attacks. Clin Neuropharmacol 23:164-168.
14. Costall B, Jones BJ, Kelly ME, Naylor RJ, Tomkins DM (1989). Exploration of mice in a black and white test box: Validation as a model of anxiety. Pharmacol Biochem Behav 32:777-785.
15. Crawley JN (1981). Neuropharmacologic specitivity of a simple animal model for the behavioural actions of benzodiazepines. Pharmacol Biochem Behav 15:695-699.
16. den Boer JA, Slaap BR (1998). Review of current treatment in panic disorder. Int Clin Psychopharmacol 13:S25-S30.
17. den Boer JA, Westenberg HGM (1990). Serotonin function in panic disorder - A double blind placebo controlled-study with fluvoxamine and ritanserin. Psychopharmacology 102:85-94.
18. Durand M, Berton O, Aguerre S, Endo L, Combourieu I, Mormède P, Chaouloff F (1999). Effects of repeated fluoxetine on anxiety-related behaviours, central serotonergic systems, and the corticotropic axis in SHR and WKY rats. Neuropharmacology 38:893-907.
19. 1A receptor antagonist WAY100635. Br J Pharmacol 130:1713-1719.
20. Figgitt DP, McClellan KJ (2000). Fluvoxamine - An updated review of its use in the management of adults with anxiety disorders. Drugs 60:925-954.
21. File SE, Hyde JRG (1979). A test of anxiety that distinguishes between the action of benzodiazepines and those of other minor tranquilizers and stimulants. Pharmacol Biochem Behav 11:65-69.
22. File SE, Pellow S (1984). The anxiogenic action of FG 7142 in the social interaction test is reversed by chlordiazepoxide and Ro 15-1788 but not by CGS 8216. Arch Int Pharmacodyn Ther 271:198-205.
23. 1A receptor function. Pharmacol Biochem Behav 62:695-701.
24. Gardner CR, Guy AP (1984). A social interaction model of anxiety sensitive to acutely administered benzodiazepines. Drug Dev Res 4:207-216.
25. Green S, Hodges H (1991). Animal models of anxiety. In: Behavioural Models in Psychopharmacology. Willner P (editor). Cambridge: Cambridge University Press, pp. 21-49.
26. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ (1995). Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology 120:57-66.
27. Griebel G, Rodgers RJ, Perrault H, Sanger DJ (1997). Risk assessment behaviour: Evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus maze. Pharmacol Biochem Behav 57:817-827.
28. Griebel G, Cohen C, Perrault G, Sanger DJ (1999). Behavioural effects of acute and chronic fluoxetine in Wistar-Kyoto rats. Physiol Behav 67:315-320.
29. Handley SL, Mithani S (1994). Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behavior. Naunyn-Schieideberg's Arch Pharmacol 327:1-5.
30. Hascoët M, Bourin M, Colombel MC, Fiocco AJ, Baker GB (2000). Anxiolytic-like effects of antidepressants in a four-plate test in mice. Pharmacol Biochem Behav 65:339-344.
31. Jenck F, Moreau J-L, Martin JR (1995). Dorsal periaqueductal gray-induced aversion as a simulation of panic anxiety: Elements of face and predictive validity. Psychiatry Res 57:181-191.
32. 2C receptor agonists and fluoxetine in a model of panic-anxiety in rats. Eur Neuropsychopharmacol 8:161-168.
33. Jones N, King SM (2001). Influence of circadian phase and test illumination on pre-clinical models of anxiety. Physiol Behav 72:99-106.
34. Jones N, Duxon MS, King SM (2002). Ethopharmacological analysis of the unstable elevated exposed plus maze, a novel model of extreme anxiety: Predictive validity and sensitivity to anxiogenic agents. Psychopharmacology 161:314-323.
35. Kasper S, Resinger E (2001). Panic disorder: The place of benzodiazepines and selective serotonin reuptake inhibitors. Eur Neuropsychopharmacol 11:307-321.
36. Kent JM, Coplan JD, Gorman JM (1998). Clinical utility of the selective reuptake inhibitors in the spectrum of anxiety. Biol Psychiatry 44:812-824.
37. King SM (1999a). Escape-related behaviours in an unstable elevated and exposed environment I. A new behavioural model of extreme anxiety. Behav Brain Res 98:113-126.
38. King SM (1999b). Escape-related behaviours in an unstable elevated and exposed environment II. Long term sensitisation after repetitive electrical stimulation of the rodent midbrain defence system. Behav Brain Res 98:127-142.
39. King SM (1999c). Maturational and gender differences in rodent escape strategies: Possible implications for preclinical models of anxiety. Psychobiology 27:513-520.
40. Lightowler S, Kennett GA, Williamson IJR, Blackburn TP, Tulloch IF (1994). Anxiolytic-like effect of paroxetine in a rat social interaction test. Pharmacol Biochem Behav 49:281-285.
41. Lister RG (1987). The use of the plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180-185.
42. Molchanov ML, Guimarães FS (1999). Defense reaction induced by metabotropic glutamate receptor agonists microinjected into the dorsal periaqueductal gray of rats. Braz J Med Biol Res 32:1533-1537.
43. 1A receptor-mediated inhibition of panic-like behaviours in rats. Psychopharmacology 131:321-328.
44. Nutt DJ (1991). Anxiety and its therapy: Today and tomorrow. In: New Concepts in Anxiety. Briley M, File SE (editors). London: Macmillan, pp. 1-12.
45. Onaivi ES, Martin BR (1989). Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Prog Neuro-Psychopharmacol Biol Psychiatry 13:963-976.
46. Pähkla R, Kask A, Rägo L (2000). Differential effects of beta-carbolines and antidepressants on rat exploratory activity in the elevated zero-maze. Pharmacol Biochem Behav 65:737-742.
47. Pellow S, Chopin P, File SE, Briley M (1985). Validation of open: Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167.
48. Pollack MH, Marzol PC (2000). Panic: Course, complications and treatment of panic disorder. J Psychopharmacol 14:S25-S30.
49. Rickels K, Downing R, Schweizer F (1993). Antidepressants for the treatment of GAD. Arch Gen Psychiatry 47:899-907.
50. Rodgers RJ (1997). Animal models of 'anxiety': Where next? Behav Pharmacol 8:477-496.
51. Rodgers RJ, Cole JC (1994). The elevated plus maze: Pharmacology, methodology and ethology. In: Ethology and Psychopharmacology. Cooper SJ, Hendrie CA (editors). Chichster: John Wiley and Sons, pp. 9-44.
52. Rodgers RJ, Cole JC, Abouaifa K, Stephenson LH (1995). Ethopharmacological analysis of the effects of putative 'anxiogenic' agents in the mouse elevated plus-maze. Pharmacol Biochem Behav 52:805-813.
53. Sánchez C, Meier E (1997). Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology 129:197-205.
54. Saran A, Halaris A (1989). Panic attack precipitated by fluoxetine. J Neuropsychiatry Clin Neurosci 1:219-220.
55. Schenberg LC, Bittencourt AS, Sudre ECM, Vargas LC (2001). Modelling panic attacks. Neurosci Biobehav Rev 25:647-659.
56. Schenberg LC, Capucho LB, Vatanabe RO, Vegas LC (2002). Acute effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked unconditioned defensive behaviours of the rat. Psychopharmacology 159:138-144.
57. Shekhar A (1994). Effects of treatment with imipramine and clonazepam on an animal model of panic disorder. Biol Psychiatry 36:748-758.
58. Shekhar A, DiMicco JA (1987). Defense reaction elicited by injection of GABA antagonists and synthesis inhibitors into the posterior hypothalamus in rats. Neuropharmacology 26:407-417.
59. Silva MTA, Alves CRR, Santarem EMM (1999). Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze. Braz J Med Biol Res 32:333-339.
60. Silva RCB, Brandão ML (2000). Acute and chronic effects of gepirone and fluoxetine in rats tested in the elevated plus-maze: An ethological analysis. Pharmacol Biochem Behav 65:209-216.
61. 2A receptors. Methods Find Exp Clin Pharmacol 21:483-490.
62. Taylor CB (1998). Treatment of anxiety disorders. In: The American Psychiatric Press Textbook of Psychopharmacology. Schatzberg AF, Nemeroff CB (editors). Washington DC: American Psychiatric Press, pp. 219-237.
63. To CT, Bagdy G (1999). Anxiogenic effect of central CCK administration is attenuated by chronic fluoxetine or ipsapirone treatment. Neuropharmacology 38:279-282.
64. To CT, Anheuer ZE, Bagdy G (1999). Effects of acute and chronic fluoxetine on CRH-induced anxiety. Neuroreport 10:553-555.
65. Vargas LC, Schenberg LC (2001). Long-term effects of clomipramine and fluoxetine on dorsal periaqueductal grey-evoked innate defensive behaviours of the rat. Psychopharmacology 155:260-268.